Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

被引：0

作者：

Debra J. Tompson

Mark Whitaker

Rennan Pan

Geoffrey Johnson

Teresa Fuller

Litza McKenzie

Vanessa Zann

Marcy Powell

Kathy Abbott-Banner

Simon Hawkins

机构：

[1] GlaxoSmithKline,Clinical Pharmacology Modelling and Simulation

[2] Medicines Research Centre,Medicine Process Delivery

[3] GlaxoSmithKline,Pharmaceutical Development

[4] Dave Jack Medicines Development Centre,Development Biostatistics

[5] GlaxoSmithKline,Global Clinical Sciences and Delivery

[6] GlaxoSmithKline,Safety and Medical Governance

[7] GlaxoSmithKline,undefined

[8] Medicines Research Centre,undefined

[9] Quotient Sciences Limited,undefined

[10] GlaxoSmithKline,undefined

[11] GlaxoSmithKline,undefined

来源：

Pharmaceutical Research | 2021年 / 38卷

关键词：

GSK2982772; modified release; once-daily; pharmacokinetics; short half-life;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1235 / 1245

页数：10

共 5 条

[1] Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
Tompson, Debra J.
Whitaker, Mark
Pan, Rennan
Johnson, Geoffrey
Fuller, Teresa
McKenzie, Litza
Zann, Vanessa
Powell, Marcy
Abbott-Banner, Kathy
Hawkins, Simon
[J]. PHARMACEUTICAL RESEARCH, 2021, 38 (07) : 1235 - 1245
[2] Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
Tompson, Debra
Whitaker, Mark
Pan, Rennan
Johnson, Geoffrey
Fuller, Teresa
Zann, Vanessa
McKenzie, Litza
Abbott-Banner, Kathy
Hawkins, Simon
Powell, Marcy
[J]. PHARMACEUTICAL RESEARCH, 2022, 39 (01) : 153 - 165
[3] Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
Debra Tompson
Mark Whitaker
Rennan Pan
Geoffrey Johnson
Teresa Fuller
Vanessa Zann
Litza McKenzie
Kathy Abbott-Banner
Simon Hawkins
Marcy Powell
[J]. Pharmaceutical Research, 2022, 39 : 153 - 165
[4] Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug - As shown by once-daily divalproex-ER
Dutta, Sandeep
Reed, Ronald C.
[J]. CLINICAL DRUG INVESTIGATION, 2006, 26 (12) : 681 - 690
[5] Functional Half-Life is a Meaningful Descriptor of Steady-State Pharmacokinetics of an Extended-Release Formulation of a Rapidly Cleared DrugAs Shown by Once-Daily Divalproex-ER
Sandeep Dutta
Ronald C. Reed
[J]. Clinical Drug Investigation, 2006, 26 : 681 - 690

← 1 →